American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Instagram Outage Disrupts Thousands of U.S. Users 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
PHOENIX, Feb. 14, 2017 -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Santosh Vetticaden, MD, PhD, Interim Chief Executive Officer, and Chief Medical Officer, and Darryl Baker, Chief Financial Officer, will present at the 2017 RBC Capital Markets Global Healthcare Conference as follows:
| Date: | Thursday, February 23, 2017 | |
| Time: | 1:35 p.m. Eastern Standard Time | |
| Location: | The New York Palace | |
The presentation will be webcast live at the aforementioned time as well as archived for 90 days thereafter, via the Company’s website at www.insysrx.com, under the Investors Section or at http://www.veracast.com/webcasts/rbc/healthcare2017/21210290235.cfm.
About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients.
Investor Contact: Lisa M. Wilson Email: [email protected]
